233 related articles for article (PubMed ID: 37425528)
1. Faricimab Effectively Resolves Intraretinal Fluid and Preserves Vision in Refractory, Recalcitrant, and Nonresponsive Neovascular Age-Related Macular Degeneration.
Cheng AM; Joshi S; Banoub RG; Saddemi J; Chalam KV
Cureus; 2023 Jun; 15(6):e40100. PubMed ID: 37425528
[TBL] [Abstract][Full Text] [Related]
2. Short-Term Outcomes of Faricimab in Patients with Neovascular Age-Related Macular Degeneration on Prior Anti-VEGF Therapy.
Szigiato A; Mohan N; Talcott KE; Mammo DA; Babiuch AS; Kaiser PK; Ehlers JP; Rachitskaya A; Yuan A; Srivastava SK; Sharma S
Ophthalmol Retina; 2024 Jan; 8(1):10-17. PubMed ID: 37673396
[TBL] [Abstract][Full Text] [Related]
3. Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration.
Leung EH; Oh DJ; Alderson SE; Bracy J; McLeod M; Perez LI; Bottini A; Chin Yee D; Mukkamala K
Clin Ophthalmol; 2023; 17():1287-1293. PubMed ID: 37181079
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes of Faricimab in Patients with Previously Treated Neovascular Age-Related Macular Degeneration.
Pandit SA; Momenaei B; Wakabayashi T; Mansour HA; Vemula S; Durrani AF; Pashaee B; Kazan AS; Ho AC; Klufas M; Regillo C; Yonekawa Y; Hsu J; Kuriyan A; Chiang A
Ophthalmol Retina; 2024 Apr; 8(4):360-366. PubMed ID: 37913992
[TBL] [Abstract][Full Text] [Related]
5. Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration.
Kishi M; Miki A; Kamimura A; Okuda M; Matsumiya W; Imai H; Kusuhara S; Nakamura M
J Clin Med; 2023 Aug; 12(15):. PubMed ID: 37568546
[TBL] [Abstract][Full Text] [Related]
6. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes.
Agostini H; Abreu F; Baumal CR; Chang DS; G Csaky K; Demetriades AM; Kodjikian L; Lim JI; Margaron P; Monés JM; Peto T; Ricci F; Rüth M; Singh RP; Stoilov I; Swaminathan B; Willis JR; Westenskow PD
Graefes Arch Clin Exp Ophthalmol; 2024 Jun; ():. PubMed ID: 38847896
[TBL] [Abstract][Full Text] [Related]
7. Short-term outcomes of intravitreal faricimab for refractory neovascular age-related macular degeneration.
Aljundi W; Munteanu C; Seitz B; Abdin AD
Graefes Arch Clin Exp Ophthalmol; 2024 Apr; ():. PubMed ID: 38607409
[TBL] [Abstract][Full Text] [Related]
8. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
Park DH; Sun HJ; Lee SJ
Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
[TBL] [Abstract][Full Text] [Related]
9. Real-World Outcomes of Faricimab Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
Quah NQX; Javed KMAA; Arbi L; Hanumunthadu D
Clin Ophthalmol; 2024; 18():1479-1490. PubMed ID: 38827773
[TBL] [Abstract][Full Text] [Related]
10. Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration.
Ng B; Kolli H; Ajith Kumar N; Azzopardi M; Logeswaran A; Buensalido J; Mushtaq B; Chavan R; Chong YJ
Life (Basel); 2024 Jan; 14(2):. PubMed ID: 38398702
[TBL] [Abstract][Full Text] [Related]
11. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
Hamid MA; Abdelfattah NS; Salamzadeh J; Abdelaziz STA; Sabry AM; Mourad KM; Shehab AA; Kuppermann BD
Int J Retina Vitreous; 2021 Apr; 7(1):26. PubMed ID: 33795022
[TBL] [Abstract][Full Text] [Related]
12. Impact of intravitreal ranibizumab, aflibercept and bevacizumab on retinal ganglion cell and nerve fibre layer thickness in Neovascular age-related macular degeneration.
Abu Dail Y; Seitz B; Sideroudi H; Abdin AD
Acta Ophthalmol; 2023 May; 101(3):330-341. PubMed ID: 36345883
[TBL] [Abstract][Full Text] [Related]
13. Association Between Visual Acuity and Residual Retinal Fluid Following Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-analysis.
Patil NS; Mihalache A; Dhoot AS; Popovic MM; Muni RH; Kertes PJ
JAMA Ophthalmol; 2022 Jun; 140(6):611-622. PubMed ID: 35551359
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
[TBL] [Abstract][Full Text] [Related]
15. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration.
Braimah IZ; Agarwal K; Mansour A; Chhablani J;
Br J Ophthalmol; 2018 Jan; 102(1):91-96. PubMed ID: 28596286
[TBL] [Abstract][Full Text] [Related]
16. Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration.
Marquis LM; Mantel I
Graefes Arch Clin Exp Ophthalmol; 2020 Aug; 258(8):1591-1596. PubMed ID: 32399582
[TBL] [Abstract][Full Text] [Related]
17. One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration.
Rush RB
Clin Ophthalmol; 2023; 17():2201-2208. PubMed ID: 37547172
[TBL] [Abstract][Full Text] [Related]
18. Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study.
Saenz-de-Viteri M; Recalde S; Fernandez-Robredo P; López Gálvez MI; Arias Barquet L; Figueroa MS; García-Arumí J; García-Layana A;
Acta Ophthalmol; 2021 Dec; 99(8):861-870. PubMed ID: 33720541
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor.
Soares RR; Mellen P; Garrigan H; Obeid A; Wibbelsman TD; Borkar D; Ho AC; Hsu J
Ophthalmol Retina; 2020 Feb; 4(2):134-140. PubMed ID: 31540854
[TBL] [Abstract][Full Text] [Related]
20. TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration.
Khanani AM; Guymer RH; Basu K; Boston H; Heier JS; Korobelnik JF; Kotecha A; Lin H; Silverman D; Swaminathan B; Willis JR; Yoon YH; Quezada-Ruiz C
Ophthalmol Sci; 2021 Dec; 1(4):100076. PubMed ID: 36246941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
